💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Tonix Pharma completes pharmacokinetic bridging study for lead candidate Tonmya; shares up 3%

Published 05/24/2018, 09:54 AM
© Reuters.  Tonix Pharma completes pharmacokinetic bridging study for lead candidate Tonmya; shares up 3%
TNXP
-
  • Tonix Pharmaceuticals (TNXP +3.4%) moves closer to an NDA filing for posttraumatic stress disorder (PTSD) med Tonmya (cyclobenzaprine HCl sublingual tablets) with the conclusion of a multi-dose pharmacokinetic bridging study with the reference listed drug (RTD) AMRIX (cyclobenzaprine HCl extended-release capsules).
  • Preliminary data showed plasma levels and exposure of 5.6 mg of Tonmya were less than 30 mg of AMRIX after 20 days of dosing. Additionally, the systemic exposure of cyclobenzaprine and its principal active metabolite norcyclobenzaprine from Tonmya was less than AMRIX at steady-state. Adverse event data were as expected.
  • The aim of the bridging study is the affirm the validity of using safety data on AMRIX to support the Tonmya marketing application under the FDA's abbreviated 505(b)(2) pathway which allows the inclusion of data generated by others.
  • Now read: Novartis Pushes To Advance Kymriah, Will A Second Indication Be Enough?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.